Gene optimization leads to robust expression of human respiratory syncytial virus nucleoprotein and phosphoprotein in human cells and induction of humoral immunity in mice

Journal of Virological Methods

Volumn 158, Issue 1-2, 2009, Pages 93-99

  Simabuco, Fernando M ^a   Tamura, Rodrigo E ^a   Carromeu, Cassiano ^a   Farinha Arcieri, Luis E ^a   Ventura, Armando M ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

DNA vaccine; Gene optimization; Human respiratory syncytial virus; Nucleoprotein; Phosphoprotein

Indexed keywords

DNA VACCINE; NUCLEOPROTEIN; PHOSPHOPROTEIN; RNA POLYMERASE; RNA POLYMERASE II;

ARTICLE; CONTROLLED STUDY; GENE SEQUENCE; GENE SYNTHESIS; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; HUMORAL IMMUNITY; IMMUNIZATION; IMMUNOFLUORESCENCE; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; RESPIRATORY SYNCYTIAL PNEUMOVIRUS; VIRUS REPLICATION; VIRUS STRAIN; WESTERN BLOTTING;

ANIMALS; ANTIBODIES, VIRAL; FEMALE; HUMANS; MICE; MICE, INBRED BALB C; NUCLEOPROTEINS; PHOSPHOPROTEINS; RESPIRATORY SYNCYTIAL VIRUS VACCINES; RESPIRATORY SYNCYTIAL VIRUS, HUMAN; VIRAL PROTEINS;

HUMAN RESPIRATORY SYNCYTIAL VIRUS; HYDRANGEA RINGSPOT VIRUS; MUS;

EID: 64949149894     PISSN: 01660934     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jviromet.2009.01.024     Document Type: Article

References (30)

1. Becker Y. Respiratory syncytial virus (RSV) evades the human adaptive immune system by skewing the Th1/Th2 cytokine balance toward increased levels of Th2 cytokines and IgE, markers of allergy. Virus Genes 33 (2006) 235-252
2. Bowman M.C., Smallwood S., and Moyer A. Dissection of individual functions of the Sendai virus phosphoprotein in transcription. J. Virol. 73 (1999) 6474-6483
3. Boxus M., Tignon M., Roels S., Toussaint J.F., Walravens K., Benoit M.A., Coppe P., Letesson J.J., Letellier C., and Kerkhofs P. DNA immunization with plasmids encoding fusion and nucleocapsid proteins of bovine respiratory syncytial virus induces a strong cell-mediated immunity and protects calves against challenge. J. Virol. 81 (2007) 6879-6889
4. Collins P.L., Chanock R.M., and Murphy B.R. Respiratory syncytial virus. In: Fields B.N., Howley P.M., Griffin D.E., Lamb R.A., Martin M.A., Roizman B., Straus S.E., and Knipe D.M. (Eds). Fields Virology (2001), Lippincott Williams & Wilkins, Philadelphia 1443-1485
5. Curran J., Marq J.B., and Kolakofsky D. An N-terminal domain of the Sendai paramyxovirus P protein acts as a chaperone for the NP protein during the nascent chain assembly step of genome replication. J. Virol. 69 (1995) 849-855
6. Fulginiti V.A., Eller J.J., Sieber O.F., Joyner J.W., Minamitani M., and Meiklejohn G. Respiratory virus immunization I. A field trial of two inactivated respiratory virus vaccines; an aqueous trivalent parainfluenza virus vaccine and an alum-precipitated respiratory syncytial virus vaccine. Am. J. Epidemiol. 89 (1969) 435-438
7. García J., García-Barreno B., Vivo A., and Melero J.A. Cytoplasmic inclusions of respiratory syncytial virus-infected cells: formation of inclusion bodies in transfected cells that co-express the nucleoprotein, the phosphoprotein, and the 22K protein. Virology 195 (1993) 243-247
8. Hall C.B., Powell K.R., Macdonald N.E., Gala C.L., Menegus M.E., Suffin S.C., and Cohen H.J. Respiratory syncytial viral infection in children with compromised immune function. N. Engl. J. Med. 315 (1986) 77-81
9. Han L.L., Alexander J.P., and Anderson L.J. Respiratory syncytial virus pneumonia among the elderly: an assessment of disease burden. J. Infect. Dis. 179 (1999) 25-30
10. Holberg C.J., Wright A.L., Martinez F.D., Ray C.G., Taussig L.M., and Lebowitz M.D. Risk factors for respiratory syncytial virus-associated lower respiratory illnesses in the first year of life. Am. J. Epidemiol. 133 (1991) 1135-1151
11. Horikami S.M., Curran J.D., Kolakofsky D., and Moyer S.A. Complexes of Sendai virus NP-P and P-L proteins are required for defective interfering particle genome replication in vitro. J. Virol. 66 (1992) 4901-4908
12. Jansen R.P. mRNA localization: message on the move. Nat. Rev. Mol. Cell. Biol. 2 (2001) 247-256
13. Joffe S., Ray G.T., Escobar G.J., Black S.B., and Lieu T.A. Cost-effectiveness of respiratory syncytial virus prophylaxis among preterm infants. Pediatrics 104 (1999) 419-427
14. Kim H.W., Canchola J.G., Brandt C.D., Pyles G., Chanock R.M., Jensen K., and Parrot R.H. Respiratory syncytial virus disease in infants despite prior administration of antigenic inactivated vaccine. Am. J. Epidemiol. 89 (1969) 422-434
15. Lemanske R.F. Viral infections and asthma inception. J. Allergy Clin. Immunol. 114 (2004) 1023-1026
16. Meric C., Spehner D., and Mazarin V. Respiratory syncytial virus nucleocapsid protein (N) expressed in insect cells forms nucleocapsid-like structures. Virus Res. 31 (1994) 187-201
17. Olson M.R., and Varga S.M. CD8 T cells inhibit respiratory syncytial virus (RSV) vaccine-enhanced disease. J. Immunol. 179 (2007) 5415-5424
18. Orvell C., Norrby E., and Mufson M.A. Preparation and characterization of monoclonal antibodies directed against five structural components of human respiratory syncytial virus subgroup B. J. Gen. Virol. 68 (1987) 3125-3135
19. Sasaki S., Takeshita F., Xin K., Ishii N., and Okuda K. Adjuvant formulations and delivery systems for DNA vaccines. Methods 31 (2003) 243-254
20. Schmidt A.C., Johnson T.R., Openshaw P.J.M., Braciale T.J., Falsey A.R., Anderson L.J., Wertz G.W., Groothuis J.R., Prince G.A., Melero J.A., and Graham B.S. Respiratory syncytial virus and other pneumoviruses: a review of the international symposium-RSV 2003. Virus Res. 106 (2004) 1-13
21. Simabuco F.M., Carromeu C., Farinha-Arcieri L.E., Tamura R.E., and Ventura A.M. Production of polyclonal antibodies against the human respiratory syncytial virus nucleoprotein and phosphoprotein expressed in Escherichia coli. Protein Express. Purif. 53 (2007) 209-215
22. Spehner D., Drillien R., and Howley P.M. The assembly of the measles virus nucleoprotein into nucleocapsid-like particles is modulated by the phosphoprotein. Virology 232 (1997) 260-268
23. Taylor G., Bruce C., Barbet A.F., Wyld S.G., and Thomas L.H. DNA vaccination against respiratory syncytial virus in young calves. Vaccine 23 (2005) 1242-1250
24. Ternette N., Stefanou D., Kuate S., Überla K., and Grunwald T. Expression of RNA virus proteins by RNA polymerase II dependent expression plasmids is hindered at multiple steps. Virol. J. 4 (2007) 51
25. Ternette N., Tippler B., Uberla K., and Grunwald T. Immunogenicity and efficacy of codon optimized DNA vaccines encoding the F-protein of respiratory syncytial virus. Vaccine 25 (2007) 7271-7279
26. Terrosi C., Di Genova G., Savellini G.G., Correale P., Blardi P., and Cusi M.G. Immunological characterization of respiratory syncytial virus N protein epitopes recognized by human cytotoxic T lymphocytes. Viral Immunol. 20 (2007) 399-406
27. Trépanier P., Payment P., and Trudel M. Concentration of human respiratory syncytial virus using ammonium sulfate, polyethylene glycol or hollow fiber ultracentrifugation. J. Virol. Methods 3 (1981) 201-211
28. Ulmer J.B., DeWitt C.M., Chastain M., Friedman A., Donnelly J.J., McClements W.L., Caulfield M.J., Bohannon K.E., Volkin D.B., and Evans R.K. Enhancement of DNA vaccine potency using conventional aluminum adjuvants. Vaccine 18 (1999) 18-28
29. Vaughan K., Rhodes G.H., and Gershwin L.J. DNA immunization against respiratory syncytial virus (RSV) in infant rhesus monkeys. Vaccine 23 (2005) 2928-2942
30. Wurm T., Chen H., Hodgson T., Britton P., Brooks G., and Hiscox J.A. Localization to the nucleolus is a common feature of coronavirus nucleoproteins, and the protein may disrupt host cell division. J. Virol. 75 (2001) 9345-9356